Refixia Nonacog Beta Pegol: INFARMED Recommends Funding for Children Under 12 With Haemophilia B
November 6, 2026
INFARMED has recommended public funding for Refixia nonacog beta pegol in the treatment and prophylaxis of bleeding in children under 12 with haemophilia B. The public assessment report, dated 5 November 2026, records a favourable decision dated 29 October 2026. It rests on two single-arm trials, and the report says neither trial is suited to assessing added therapeutic value.
Refixia nonacog beta pegol: the decision and its scope
Refixia is a recombinant human factor IX, purified and conjugated to 40 kDa polyethylene glycol. Novo Nordisk A/S holds the marketing authorisation. It comes in three vial strengths, 500, 1,000 and 2,000 IU per 4 ml, under registrations 5724505, 5724521 and 5724513. It is prescription-only and restricted under article 118(c) of Decree-Law 176/2006.
Let Google know we are your trusted source.
Add our editorial as a preferred source in your search results.
Value Science Weekly
The week in health technology assessment, market access and health economics — what moved, and what it means.